Announcements Trials
Browse Landscape

Phase

Phase NA 12Phase 1 4Phase 3 3Phase 2 2Phase 1/2 2Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gynecologic 1

Conditions

Hematologic Neoplasms 1

Interventions

Cytarabine 25Cyclophosphamide 23venetoclax 15Methotrexate 15Daunorubicin 14Dexamethasone 13Vincristine 11Etoposide 11Idarubicin 9Decitabine 9Busulfan 9Azacitidine 9fludarabine 8Radiotherapy 8Prednisone 8Stem Cell Transplantation 7Mercaptopurine 7Doxorubicin 7Asparaginase 7pegaspargase 6fludarabine phosphate 6blinatumomab 6Granulocyte Colony-Stimulating Factor 6Gemtuzumab 6Filgrastim 6Thiotepa 5Methylprednisolone 5Dasatinib 5Whole-Body Irradiation 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Practice Guidelines as Topic × Other hematologic neoplasm × Clear all
NCT03870750 2026-01-12

Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

Fred Hutchinson Cancer Center

Phase 2/3 Terminated
458 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡